ADMA Biologics reported total revenue of $141.1 million for the third quarter 2026, surpassing analyst expectations of $139.8 million. The results were driven by the continued commercial momentum of the company's high-margin hyperimmune product, Asceniv, which saw revenue grow 31% year-over-year to $124.7 million.
Key Highlights
- Gross margin expanded to 71% compared to 56% in the prior-year period, reflecting favorable product mix and benefits from yield-enhanced manufacturing processes.
- Bivigam revenue fell to $15.4 million from $19.4 million sequentially as the company maintained disciplined pricing despite competitive pressures in the standard immune globulin market.
- Management increased full-year 2026 outlook for adjusted net income to at least $180 million while reiterating total revenue guidance of at least $530 million.